A New Risk Prediction Model for VTE in Patients With Multiple Myeloma

There is an unmet need for a risk prediction model capable of personalizing the intensity of thromboprophylaxis based on the VTE and bleeding risk of individual patients. The retrospective cohort study included 934 patients with multiple myeloma, treated at Cleveland Clinic between January 2008 and December 2018. 105 out of 934 patients experienced a VTE within the first 12 months of treatment initiation. Fortesumib, lenalidomide, dexamethasone was the most common induction regimen given to 41% of patients.